Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
|
|
- Darcy Hawkins
- 6 years ago
- Views:
Transcription
1
2 Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where we can make a difference, Laurus combined innovation with efficiency by developing cost effective processes while simultaneously investing in suitable capacities to ensure reliability of supply. Laurus offers its globally compliant cgmp facilities, along with its chemistry expertise and experience, to its customers for contract development and manufacturing of APIs and intermediates. With proven capabilities to meet and exceed the clients requirements in terms of quality, regulatory and IP needs as well as cost targets, Laurus Labs aims to provide a total API solution to the global market. Laurus is continuously extending its portfolio to include focus on molecules in other therapy areas where it feels it can establish a leading position. Laurus is one of the world s leading suppliers of antiretroviral APIs & intermediates and we believe our low cost technologies in this critical segment will help increase access to medicine for those in need throughout the world. Laurus works closely with leading innovators, global health organizations and providers to ensure cost reduction targets are met without compromising quality standards. With state-of-the-art facilities to handle highly potent materials at both developmental and commercial scale, Laurus considers Oncology one of its core competencies and offers a comprehensive range of APIs in this segment. 1 2
3 Business Units Laurus is forward integrating into finished dosage forms (FDF) to create more value, generated through its cost effective processes and large capacities in the API business, for its customers. Trusted, recognized and credible API solution provider Forward Integration API and Finished dosage solution provider The Finished Dosage Form Development center is an integral part of Laurus R&D, comprising of Formulation and Analytical Research, Clinical Pharmacodynamics and Pharmacokinetics, Regulatory Affairs, Packaging Development, Intellectual Property Management and Developmental QA departments. Laurus has dedicated formulation research labs, laboratory scale clinical supply facility & analytical research labs capable of developing different types of dosage form. As Laurus has established a strong competency in development and manufacture of potent molecules, it is also our intention to establish capability to manufacture potent oral products. In parallel, Laurus is establishing state of art oral finished dosage facilities conforming to international regulatory standards. The facility will have a pilot plant and initial commercial capacity of 1 billion units, expanding to 5 billion units over time, with investment of US$50million. We are building on Laurus R&D s strengths in chemistry research, process chemistry, active pharmaceutical ingredient production and regulatory filings to forward integrate to FDF Business. FDF business is committed to strengthen and further enhance Laurus vision of becoming a leading player in offering integrated solutions to global pharmaceutical needs. Market API Price Laurus API Value Add Laurus API COGS We Solicit Partnerships / Alliances with potential business partners for : Out-licensing of projects from our development pipeline Joint Product Development with manufacture and supply of Finished Dosage Forms Work with partner jointly on early launch opportunities - advantages of API or FDF innovation - Licensing/Royalty/Profit Share based business model Life cycle management utilizing Laurus ability to be the lastman-standing in key molecules Site Transfer and Contract manufacture for the Regulated Markets Two ANDAs and one WHO dossier filed. Market FDF Price Laurus Total Value Add Laurus Finished Dosage COGS Integration Benefits Cost Effective API Process Large Capacities Continuous process improvements 3 4
4 Business Units The core-strength of Laurus is its innovative, robust & scalable chemistry - making use of which, multiple developmental candidates of client organizations have been handled at all stages of drug lifecycle right from route identification through to custom synthesis and from early clinical through to commercialization. Even while handling semi-mature processes of late-phase clinical candidates OR while conducting tech-transfer of mature processes of marketed APIs &/ or KSMs for eventual contract manufacture, our development & manufacturing teams have a tight focus on aspects such as performance at scale, continuous process improvement, securing and de-risking supply chain et al thus providing an efficient, compliant, cost-effective and long-term commercial drug substance solution. The strong analytical chemistry team at Laurus works closely with the chemical development & tech-transfer teams as the process evolves & provides all necessary and phase-appropriate support to the client organizations involved on their drug substance as well as drug product analytical development needs. The drug product development team at Laurus is fully capable & equipped to develop all type of formulations both for NCEs & Generics and other specialty products. This capability is ably complemented by the comprehensive analytical infrastructure in place. While the Indian operations service the global clients, taking into cognizance a need for intensive iteration with their CRO partners of a section of drug discovery, pharmoutsourcers in USA, Laurus established a fully owned subsidiary Laurus Synthesis Inc. in the drug-discovery hotbed of Boston, MA. The high caliber team here can support clients on their early to late-stage chemical development needs and work in tandem with the India site for providing a complete scale-up solution to the North American client organizations bringing to them, literally the best of both worlds. With strengths in flexi-scale drug substance manufacturing & phase appropriate chemical & analytical development capabilities, Laurus labs is well positioned to meet all NCE drug substance needs of the client, preclinical through to commercial manufacture. Utilizing the core competencies of the specialized work-force and the manufacturing expertise within the larger organization, Laurus synthesis division offers services in two distinct segments of Contract Manufacture & Contract Development. CONTRACT DEVELOPMENT Drug Substance Services Chemical process development Drug substance manufacture, including HPAPIs CMC & regulatory support Custom synthesis Analytical Development Services Method development Method validation Stability studies Impurity identification, characterization Reference standard characterization Product Development Services Pre-formulation studies Dosage form development for NCEs Formulation development for ANDA submissions CONTRACT MANUFACTURE APIs & Starting Material Tech-transfer from client sites aided by effective project management Secure RM supply chain by continuing the existing sources & identifying new cost-effective sources &/or back-integrating the manufacture where possible Custom build and dedicate equipment trains/ blocks/ manufacturing facilities as required Niche Solutions Large-scale chiral separations utilizing the pilot & commercial-scale SMB capabilities Collaborative models including IP-share, revenueshare models of development, facility deployment and manufacture 5 6
5 Business Units There is a strong and welcome trend worldwide of consumers adopting a lifestyle of holistic wellness, in which nutritional supplements play an important role. Laurus Labs has been at the forefront of developing innovative and patented technologies and manufacture of highly pure, well characterized specialty ingredients for use in dietary supplements and cosmeceutical products. Laurus has gained the leadership position in manufacture and supply of nature identical and highly pure polyphenols (Curcumin, Resveratrol, Pterostilbene etc.) and successfully developed technologies for carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine, Curcumin etc. for their enhanced bioavailability/controlled absorption. Laurus also manufacture natural ingredients of proven efficacy and safety for weight management, sports nutrition, joint health, metabolic disorders, eye health, skin care and general wellbeing. With manufacturing and quality rigor matching that of the pharmaceutical APIs and international compliances of GMP, Kosher, Halal and HACCP etc., our Ingredients have gained a global reputation for consistent quality and assurance of supply. 7 8
6 Facilities Research & Development Center Hyderabad Drug Substance Manufacturing Facilities Vizag Located in Hyderabad, a key pharmaceutical center of India, Laurus State of the art R&D center is the hub of focused scientific activity. The scientific teams here not only develop, optimize scientific & technological solutions but also ensure these innovations are scalable & compatible with the market realities. 10-acre campus at IKP Genome Valley 700+ scientific staff in R&D space with dedicated labs for chemical development, analytical development & formulation development Pilot plant incl. a fully contained block for high potent Manufacturing facility Small volume GMP manufacture of non-potent & highlypotent APIs USFDA, TGA, KFDA and PMDA approved Located in Visakhapatnam (Vizag), a coastal city & an emerging pharmaceutical hub, these state-of-the-art facilities have been built to the most demanding global standards. The manufacturing team here works closely with the research & development team at Hyderabad to transfer-in, validate & commercialize the manufacturing processes. Unit 1: 34-acres campus in Jawaharlal Nehru Pharma City 760,000 sft of built-up space with 1,140,000L of installed capacity Commercial-scale manufacture of non-potent & highlypotent APIs USFDA, MHRA, TGA, KFDA, WHO-cGMP and PMDA approved 9 10
7 Facilities Manufacturing Facilities Vizag Special Capabilities Unit 2: 45-acres campus in Special Economic Zone (SEZ) at Achutapuram (21km from Unit 1) Integrated manufacturing site for API and Finished Dosage Forms USFDA Inspection completed during December 2016 Unit 3: 40-acres campus in Jawaharlal Nehru Pharma City, located adjacent to Unit 1 and operating under the same FDA establishment number 450,000sft of built-up space with over 650,000 L of installed capacity Commercial-scale manufacture of APIs USFDA, WHO-cGMP and EU-GMP approved Unit 4: 44-acres campus in Achutapuram (21km from Unit 1) Manufacturing facility focused on backward integration into key starting materials and intermediates in addition to solvent recovery will be operational in 2016 Unit 5: 9-Acre site in Special Economic Zone (SEZ) at Jawaharlal Nehru Pharma City dedicated for hormonal APIs is inaugurated and operational Digitally controlled normal pressure large scale silica gel chromatography is used to manufacture APIs at the scale of 1ton/month. 6-columns with 670 mm diameter and 6 mts in height are used in coordination with Falling Film Evaporators (FFE) for fraction enrichment. T h e c o n t i n u o u s s i m u l a t e d m o v i n g b e d chromatographic system is being extensively used to separate the racemic mixture in industrial scale at Laurus. VARICOL form NOVASEP is installed with a capacity to process 15tons/month of racemic mixture
8 SYSTEMS: Quality, Regulatory, EHS and IP Quality Policy Laurus labs is committed to maintain best Quality Standards in Research & Development, Contract Services and Manufacturing of Pharmaceutical products through periodic reviews and continuous improvement of Quality Management System, and strive to enhance customer satisfaction. Regulatory Compliance Laurus Labs is fully committed to ensure that our manufacturing facilities comply with international regulations for current Good Manufacturing Practice (cgmp); Good Laboratory Practice (GLP) & all locally applicable regulatory requirements We have been inspected by most regulatory bodies including USFDA, MHRA, TGA, KFDA, WHO-cGMP and PMDA We have experience in filing DMF s in accordance with the requirements of FDA(USDMF), EDQM(CEP), ICH(ASMF in ECTD format), PMDA(J-DMF) & other agencies. We have obtained written confirmation for active substances exported to the European Union for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC Intellectual Property Committed to respect globally Laurus Labs have extensive experience in reviewing the patents and understanding the relevance of IP landscape. We also work with customers and third parties to validate the information. Laurus Labs is well versed with the procedural requirements of filing patents & have filed in various jurisdictions such as US, UK, INDIA & PCT. Guidelines, SOPs in place for handling of Client IP received & generated in course of delivery All employees are signatories to non-disclosure agreement on all proprietary information Any IP generated on projects fully sponsored by the client is owned by the client valid Intellectual Property Environment, Health & Safety Laurus is committed to; Mitigate the environmental impact of its activities, products and services Protect and promote the health and well being of its employees Equip, establish and operate its facilities to highest safety standards 13 14
9 Manufacturing Facilities Vizag, Andhra Pradesh State-of-the-Art R&D Centre Hyderabad, Telangana
Introduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationLeader in Pharmaceutical Oral Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Oral Films WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation pharmaceutical products that address unmet medical
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationPartner with the Global Leader in Drug Delivery Systems
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Northridge, CA, USA Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into Thousands
More informationPortfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO
Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation March 2017 A Leading Pharmaceutical Company #4 Leading pharmaceutical company in India 1 Market share of 4.2% With a Global Footprint Revenue Split for 9MFY17
More informationNews Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21
Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21 Even more attractive to life science and fine chemical industries Saltigo GmbH Contact: Ilona Kawan LANXESS AG Corporate Communications
More informationManagement in Pharmaceutical Industry
Master Program Management: Industrial Management Module: Chemistry for Drug Substances Management in Pharmaceutical Industry Prof. Tatsiana Savitskaya Assoc. Prof. Iryna Kimlenka Lectures 5,6 The Key Aspects:
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation September 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.4% With a Global Footprint Revenue
More informationDrug Development Services
Drug Development Services Speaker Introduction Nik Burlew Vice President Regulatory and Strategic Development 25 Years in Pharma: Development, MFG and QA. Consulting for the last 13 years primarily to
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationExclusive Manufacturing Solutions
Exclusive Manufacturing Solutions Helsinn Advanced Synthesis SA Making the difference with highest quality manufacturing facilities, expertise, investments and commitment 1 Index of Contents Building
More informationCadila Healthcare Limited Investor Presentation August 2014
Cadila Healthcare Limited Investor Presentation August 2014 Well integrated pharma player with global footprints >60 years Operational experience $ 1 bn + Global Revenues ~ 7% of sales Spent on R&D annually
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationA Global CRO STRONGER TOGETHER
A Global CRO STRONGER TOGETHER About us Unique Service Offering the first agrochemical CRO to offer a truly global service Part of the Eurofins Scientific Group of companies, Eurofins Agroscience Services
More information"Saltigo - Customized Competence"
News Release Saltigo GmbH Contact: Udo Erbstößer LANXESS Deutschland GmbH Corporate Communications Trade & Technical Press 51369 Leverkusen Germany Phone +49 214 30-54529 Fax +49 214 30-44865 udo.erbstoesser@lanxess.com
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationGlossary of Abbreviations
Glossary of Abbreviations ANDA APhA Abbreviated New Drug Application American Pharmaceutical Association API Active Pharmaceutical Ingredient BA/BE Bioavailability/Bioequivalence BE Bioequivalence Bio
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationProquina A Bayer Company
Proquina A Bayer Company Producing Active Pharmaceutical Ingredients and Advanced Intermediates Proquina ensuring high quality in line with Bayer standards Reliable what we do, we do right As a subsidiary
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation November 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.3% With a Global Footprint Revenue
More informationBest-in-class API / HPAPI / Small Molecules Custom Manufacturing
Best-in-class API / HPAPI / Small Molecules Custom Manufacturing Tippecanoep Ham Hanau Slove enska L upča Dossenh senheim Nanning Production and process development Six production locations countless options.
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationSECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD
*ADDRESS BY SHRI ASHOK KUMAR, IAS, SECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD Shri Anand Sharmaji, Hon ble Minister of Commerce & Industry, Govt. of India,
More informationRegulatory Starting Materials An FDA Perspective
Regulatory Starting Materials An FDA Perspective Kasturi Srinivasachar Branch Chief (Acting), New Drug API Division Office of New Drug Products, OPQ/CDER/ FDA 1 CDER Reorganization Office of Pharmaceutical
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationCHINOIN PROFESSIONAL RELIABLE DEDICATED PROSTAGLANDIN EXPERTISE
CHINOIN PROFESSIONAL RELIABLE DEDICATED PROSTAGLANDIN EXPERTISE PROSTAGLANDIN EXPERTISE WITHIN CEPiA/SANOFI Sanofi is more than a pharmaceutical laboratory: it is a diversified healthcare company. It acts
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationManagement Team. Over 35 years experience in the pharmaceuticals industry
2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since
More informationAPI Selection of Starting Materials Impact on First Cycle Approval
API Selection of Starting Materials Impact on First Cycle Approval Presented by Aloka Srinivasan, Ph.D. Vice President, Regulatory Affairs May 24, 2017 Trends in Selection of Regulatory Starting Materials
More informationHealth research and innovation services
Health research and innovation services Health research and innovation services ALIDANS PROVIDES SERVICES AND PRODUCTS FOR RESEARCH AND INNOVATION (R&I) IN THE HEALTH FIELD, THANKS TO A WORLDWIDE NETWORK
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal
More informationCorporate Presentation
Corporate Presentation Safe Harbor Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation
More informationMapping Success for Commercial Cell Therapy Manufacturing 100% 50% 0% 100% 50% 0% 100% 50% Realization
BioProcess TM I N T E R N A T I O N A L C e l l T h e r a p y FACILITIES AND LOGISTICS Mapping Success for Commercial Cell Therapy Bob Preti, Ann M. Daus, Brian Hampson, and Cenk Sumen Commercializing
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
More informationKey Definitions 6/16/2015
Technology Transfer from a CDMO Perspective Joe Cobb, CPIP Director, Pharmaceutical Development Metrics Contract Services, a division of Mayne Pharma US 18-June-2015 Key Definitions CDMO Contract Development/Manufacturing
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationGlobal Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
More informationComplex Generics: Charting a new path
White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.
More informationTHE COMMON TECHNICAL DOCUMENT: TAKING INDIAN NDA PROCESS TOWARDS GLOBALIZATION
Review Article Bhalodiya H. A.*, Boda J. M., Shah J. S., Patel P. B., Vaghela J. P. Department of Quality Assurance, S. J. Thakkar Pharmacy College, Rajkot-360005, Gujarat, India. *Corresponding author
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationStarting Material Selection for Type II Drug Master Files
Starting Material Selection for Type II Drug Master Files Ronald S. Michalak Quality Assessment Lead (Acting), Division of Lifecycle API Office of New Drug Products, OPQ/CDER/ FDA CDER Reorganization Office
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationAbout Siegfried. Company Portrait
About Siegfried Company Portrait Headquartered in Zofingen, Switzerland, Siegfried operates worldwide in life sciences with production facilities in Switzerland, the USA, Malta, China, Germany and France.
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationCU Chemie Uetikon GmbH
CU Chemie Uetikon GmbH Challenges in API manufacturing UETIKN Dr. Hendrik Baumann, Commercial Director www.uetikon.com First of all... UETIKN... CNGRATULATINS to the 5th anniversary of Rapid Pharma Development
More informationHealthCaps. Quality our Priority
HealthCaps I N D I A LTD. our Priority Introduction Healthcaps India Ltd is one the largest manufacturers of high quality Empty Capsules worldwide. We are a WHO-GMP, Halal & Kosher certified company in
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationCadila Healthcare Ltd. Investor Presentation February 2010
Cadila Healthcare Ltd. Investor Presentation February 2010 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationA High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges
A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical
More informationREGULATORY AFFAIRS OUTSOURCING
REGULATORY AFFAIRS OUTSOURCING WHY SHOULD YOU OUTSOURCE? Regulatory Affairs Unit in a pharmaceutical company is a vital unit that drives the R & D efforts of the company to the market successfully. Today
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationBRUSSELS CORDENPHARMA EXPERTS TAKING CARE
CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Corden Pharma Brussels S.A. 310 rue de Ransbeek 1120 Brussels Belgium Phone +32 2 263 1411 www.cordenpharma.com/contact-us/ www.cordenpharma.com Our History 1987:
More informationCORDENPHARMA BRUSSELS EXPERTS TAKING CARE
CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Our History 1987: Peptisyntha founded by Solvay 1996: First pre-approval FDA inspection for a major peptide made by Peptisyntha for the worldwide market. Following
More informationPharmacopoeial Reference Standards
Pharmacopoeial Reference Standards Industry view point Antony Raj Gomes Head- Quality Management 1 Presentation Overview Indian Industry an update Available guidelines Industry practices Current challenges
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationCREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO
CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO STATE-OF-THE-ART GMP FACILITIES Our sites in Jena and Halle (Germany) provide a complete range
More informationPharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful
Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationAPPLICATION OUTSOURCING. for life sciences
APPLICATION OUTSOURCING for life sciences OUTSOURCE TO THE LIFE SCIENCES SPECIALIST NNIT combines the power of life sciences experience, applications expertise and GxP regulatory knowledge to deliver applicationoutsourcing
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationData Reliability - Internet
Data Reliability - Internet Wikipedia https://en.wikipedia.org/wiki/reliability_of_wikipedia Others http://www.dailymail.co.uk/health/article- 2639910/Do-NOT-try-diagnose-Wikipedia-90-medicalentries-inaccurate-say-expertsDo.html
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More informationDi Renzo Regulatory Affairs ROME - MILAN - LONDON
Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs In 1985, Di Renzo Regulatory Affairs began its regulatory consulting for medicines for human and veterinary use, food and dietary
More informationRegulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationIndian CRAMS players to cram in growth: CARE Ratings
January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationEurofins ADME BIOANALYSES Your partner in drug development
Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant
More informationVIEW POINT. The Enterprise QA Transformation Model A solution to enhance an enterprises testing maturity. Abstract. Reghunath Balaraman, Aromal Mohan
VIEW POINT The Enterprise QA Transformation Model A solution to enhance an enterprises testing maturity Reghunath Balaraman, Aromal Mohan Abstract With the increasing acceptance of testing/qa as an independent
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationDealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon.
Dealdoc Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon Oct 18 2010 Marketing agreement for Recombinant Human Insulin, Glargine, Aspart
More informationPAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationAppropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products
Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology
More informationI. DEFINITION This training under Kilimanjaro School of Pharmacy Industrial Pharmacy Teaching Unit (IPTU) is an Advanced Training Program in Drug Development, Drug Manufacturing, Regulatory & Quality Compliance.
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationRating criteria for the pharmaceuticals industry. February 2018
Rating criteria for the pharmaceuticals industry February 2018 Criteria contacts Pawan Agrawal Chief Analytical Officer CRISIL Ratings Email: pawan.agrawal@crisil.com Ramesh Karunakaran Director Rating
More information